君实公司盈利能力分析及价值提升.docxVIP

摘 要 国家提出“大众创新，大众创新”的政策，追求经济快速增长和经济高质量增长。而能够高度契合这个政策的企业通常是高新技术企业。研发是这种类型的企业提高核心竞争力的关键之一，特别是作为医药行业，研发显得尤为重要和有意义。君实公司是一家致力于开发新药物的制药公司，目前所掌握的生物大分子技术亦能在同类型技术中名列前茅，并且在中国内有优秀的开发药物的能力。君实公司目前的在研产品组合若能成功获批上市然后进入市场，所取得的利润是绝对可观的。但是君实公司目前对研发费用的投入极大，所以在未来的很长时间内君实公司是不会得到太多的利润回报。君实公司处于研发的投入期中，计划着产品研发线路拓宽后，能顺利让多中心的大型临床研究展开来，君实生物的研发的投入资本预估还会提高，而在短期内君实公司向扭亏为盈依旧存在压力。本文将以君实生物公司为例,对其相关财务数据、财务指标以及研发费用和盈利能力进行分析，目的在于提高其盈利能力,也希望能对同行业高新技术企业提供帮助。 关键词： 财务指标 研发费用 盈利能力 高新技术企业 Abstract The state proposes the policy of“mass innovation, mass innovation”to pursue rapid economic growth and high-quality economic growth. The high-tech enterprises are usually the ones that can highly fit the policy. RD is one of the key to improve the core competitiveness of this type of enterprises, especially as a pharmaceutical industry, RD is particularly important and meaningful. Junshi company is a pharmaceutical company dedicated to the development of new drugs. At present, the technology of biomacromolecule is also among the best in the same type of technology, and has excellent ability to develop drugs in China. If Junshi’s current product portfolio under research can be successfully approved for listing and then enter the market, the profits will be absolutely considerable. But Junshi company has invested a lot in RD expenses at present, and won’t get too much profit reward in a long time in the future. Junshi company is in the investment period of RD, and plans to smoothly launch multi center large-scale clinical research after the product RD line is widened. The investment capital prediction of Junshi biological RD will be improved, but there is still pressure for Junshi company to turn losses into profits in the short term. This paper will take Junshi biological company as an example to analyze its relevant financial data, financial indicators, RD costs and profitability, in order to improve its profitability, and also hope to provide help to high-tech enterprises in the same industry. Keywords: Financi